A potential therapeutic strategy in ALS involves increasing the expression of NfL, which may shift the balance from the energy-intensive neurofilament heavy chain (NfH) toward smaller, more metabolically efficient subunits. The gene discussed is NEFH; the disease is amyotrophic lateral sclerosis.